News & Updates
Filter by Specialty:
Selective TYK2 inhibitor safe, works against psoriatic arthritis
Deucravacitinib, a selective TYK2 inhibitor, is well tolerated and appears to produce marked improvements in American College of Rheumatology 20 (ACR20) and other endpoints in the treatment of patients with psoriatic arthritis (PsA), according to the results of a phase II study.
Selective TYK2 inhibitor safe, works against psoriatic arthritis
08 Mar 2022
Medication risks an acceptable trade-off for cure of IBS symptoms
Patients with irritable bowel syndrome (IBS) are willing to take on significant medication risks in exchange for a permanent cure of their symptoms, a study has found.
Medication risks an acceptable trade-off for cure of IBS symptoms
07 Mar 2022
Adherence higher, discontinuation lower with ixekizumab vs secukinumab
Psoriasis patients treated with ixekizumab show better persistence and adherence over 24 months as well as a lower risk of discontinuation than those using secukinumab, reports a recent study that used real-world data.
Adherence higher, discontinuation lower with ixekizumab vs secukinumab
07 Mar 2022
Corticosteroids up incidence of adverse events, readmissions in severe COPD
A single-institution study does not recommend the prescription of systemic corticosteroids for the treatment of severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) as this might result in an increased incidence of adverse effects and readmissions.
Corticosteroids up incidence of adverse events, readmissions in severe COPD
05 Mar 2022
Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC
In patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations*, combining niraparib with abiraterone acetate plus prednisone (AAP) in the first-line setting improved radiographic progression-free survival (rPFS) and other outcomes, results of the phase III MAGNITUDE study showed.
Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC
04 Mar 2022
Empiric antibiotic use confers no therapeutic benefit in COVID-19 pneumonia
The use of empiric antibiotic therapy appears to prevent neither deterioration nor death among patients with COVID-19 pneumonia, as shown in a Singapore study.